2026 Global: Cell Counting Market-Competitive Review (2032) report
Description
The 2026 Global: Cell Counting Market-Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for cell counting market by geography and historical trend. The scope of the report extends to sizing of the cell counting market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
The cell counting market is dominated by ten major companies: Thermo Fisher Scientific Inc., Danaher Corporation (including Beckman Coulter), Becton, Dickinson and Company (BD), Agilent Technologies Inc., Bio-Rad Laboratories Inc., Merck KGaA, F. Hoffmann-La Roche Ltd., PerkinElmer Inc., Tecan Trading AG, and DeNovix Inc.. These leaders drive innovation through automated counters, flow cytometry, and imaging platforms, addressing demands in diagnostics, bioprocessing, and research. Thermo Fisher Scientific offers comprehensive solutions from manual to cloud-integrated automated systems, ensuring seamless data management for global labs. Danaher, via Beckman Coulter, excels in high-throughput flow cytometry and imaging, prioritizing speed and reproducibility for translational research. BD provides robust cytometry tools integral to clinical and pharma workflows, while Agilent integrates precision optics for scalable, data-driven analysis.
Bio-Rad Laboratories delivers versatile counters supporting viability assays and high-content imaging, catering to academic and biotech needs. Merck KGaA contributes advanced instruments within its life sciences portfolio, emphasizing electrical impedance and fluorescence technologies. F. Hoffmann-La Roche embeds cell counting in diagnostics, leveraging regulatory-compliant, high-throughput solutions for drug discovery. PerkinElmer enhances the market with image cytometry like Cellaca PLX, focusing on cell quality and quantity analysis. Tecan Trading AG specializes in modular liquid handling platforms for efficient screening and cell culture.
DeNovix Inc. stands out with compact, user-friendly spectrophotometers and counters ideal for smaller labs, backed by intuitive software. Collectively, these firms fuel market growth projected at 8.5% CAGR to USD 18.23 billion by 2032, propelled by cell therapies and bioprocessing expansions. Strategic acquisitions, such as Danaher's integrations and PerkinElmer's Nexcelom acquisition, bolster their positions, while North America holds 38% share due to robust R&D. Innovations like AI-powered platforms and microfluidics ensure precision and reproducibility across hospitals, pharma, and institutes.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for cell counting market by geography and historical trend. The scope of the report extends to sizing of the cell counting market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
The cell counting market is dominated by ten major companies: Thermo Fisher Scientific Inc., Danaher Corporation (including Beckman Coulter), Becton, Dickinson and Company (BD), Agilent Technologies Inc., Bio-Rad Laboratories Inc., Merck KGaA, F. Hoffmann-La Roche Ltd., PerkinElmer Inc., Tecan Trading AG, and DeNovix Inc.. These leaders drive innovation through automated counters, flow cytometry, and imaging platforms, addressing demands in diagnostics, bioprocessing, and research. Thermo Fisher Scientific offers comprehensive solutions from manual to cloud-integrated automated systems, ensuring seamless data management for global labs. Danaher, via Beckman Coulter, excels in high-throughput flow cytometry and imaging, prioritizing speed and reproducibility for translational research. BD provides robust cytometry tools integral to clinical and pharma workflows, while Agilent integrates precision optics for scalable, data-driven analysis.
Bio-Rad Laboratories delivers versatile counters supporting viability assays and high-content imaging, catering to academic and biotech needs. Merck KGaA contributes advanced instruments within its life sciences portfolio, emphasizing electrical impedance and fluorescence technologies. F. Hoffmann-La Roche embeds cell counting in diagnostics, leveraging regulatory-compliant, high-throughput solutions for drug discovery. PerkinElmer enhances the market with image cytometry like Cellaca PLX, focusing on cell quality and quantity analysis. Tecan Trading AG specializes in modular liquid handling platforms for efficient screening and cell culture.
DeNovix Inc. stands out with compact, user-friendly spectrophotometers and counters ideal for smaller labs, backed by intuitive software. Collectively, these firms fuel market growth projected at 8.5% CAGR to USD 18.23 billion by 2032, propelled by cell therapies and bioprocessing expansions. Strategic acquisitions, such as Danaher's integrations and PerkinElmer's Nexcelom acquisition, bolster their positions, while North America holds 38% share due to robust R&D. Innovations like AI-powered platforms and microfluidics ensure precision and reproducibility across hospitals, pharma, and institutes.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
